aXichem (AXIC) investor relations material

Executive summary

• Net sales for Q1 2026 reached SEK 3,826 thousand, a slight increase year-over-year, with sales driven by aXiviteⓇ in Europe and the US.

• Operating loss improved to SEK -2,826 thousand from SEK -5,876 thousand year-over-year, mainly due to reduced costs related to EU feed additive approval processes.

• Significant events included the publication of a clinical study, progress with EFSA on EU approval, successful rights issue, and product registration for phenylcapsaicin in Brazil for ruminants.

Financial highlights

• Net sales increased to SEK 3,826 thousand from SEK 3,387 thousand year-over-year.

• Operating loss narrowed to SEK -2,826 thousand from SEK -5,876 thousand year-over-year.

• Profit after tax was SEK -2,883 thousand, an improvement from SEK -5,876 thousand year-over-year.

• Cash and cash equivalents at quarter-end were SEK 4,000 thousand, down from SEK 9,653 thousand year-over-year.

• Earnings per share improved to SEK -0.05 from SEK -0.10 year-over-year.

Outlook and guidance

• Continued commercialization of phenylcapsaicin under aXiphenⓇ for animal feed and aXiviteⓇ for dietary supplements is expected.

• Ongoing efforts to secure EU and additional international approvals for phenylcapsaicin in animal feed.

• Anticipated gradual increase in order intake for both animal feed and dietary supplements in coming years.